Persistence of schistosoma haematobium infection despite multiple courses of therapy with praziquantel

Clinical Infectious Diseases

Volumn 20, Issue 2, 1995, Pages 309-315

  Herwaldt, Barbara L ^a,b,c   Tao, Liang Feng ^a,b,c   Van Pelt, Willem ^a,b,c   Tsang, Victor C W ^a,b,c   Bruce, John I ^a,b,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAZIQUANTEL;

ARTICLE; CASE REPORT; DRUG EFFICACY; HOST; HOST PARASITE INTERACTION; HUMAN; MALE; PRIORITY JOURNAL; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; SCHOOL CHILD;

ANIMAL; CASE REPORT; CHILD; HUMAN; MALAWI; MALE; PARASITE EGG COUNT; PRAZIQUANTEL; SCHISTOSOMIASIS HAEMATOBIA; TRAVEL; UNITED STATES;

EID: 0028859635     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.2.309     Document Type: Article

References (41)

1. King CH, Mahmoud AAF. Drugs five years later: praziquantel. Ann Intern Med 1989; 110:290-6.
2. Day TA, Bennett JL, Pax RA. Praziquantel: the enigmatic antiparasitic. Parasitol Today 1992;8:342-4.
3. Cioli D, Pica-Mattoccia L, Archer S. Drug resistance in schistosomes. Parasitol Today 1993;9:162-6.
4. Giboda M, Loudova J, Shonova O, et al. Efficacy of praziquantel treatment of schistosomiasis in a non-endemic country: a follow-up of parasitological, clinical and immunological parameters. J Hyg Epidemiol Microbiol Immunol 1992;36:346-55.
5. Chidiac C, Beaucaire G, Mouton Y, Caillaux M, Fourrier A. Failure of the treatment by praziquantel of schistosomiasis. Interest of rectal biopsy and of long follow up. Medecine et Maladies Infectieuses 1986;5:380-4.
6. Melvin DM, Brooke MM. Laboratory procedures for the diagnosis of intestinal parasites. 3rd ed. Washington, DC: U.S. Department of Health and Human Services, 1982; HHS publication no. (CDC)85-8282.
7. Rusnak J, Hadfield TL, Rhodes MM, Gaines JK. Detection of Cryptosporidium oocysts in human fecal specimens by an indirect immunofluorescence assay with monoclonal antibodies, J Clin Microbiol 1989;27:1135-6.
8. Liang Y-S, Bruce JI, Boyd DA. Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proceedings of the First Sino-American Symposium. Taipei: National Yangming Medical College, 1987; 1:34-48.
9. Drescher KM, Rogers EJ, Bruce JI, Katz N, Dias LCS, Coles GC. Response of drug resistant isolates of Schistosoma mansoni to antischis- tosomal agents. Mem Inst Oswaldo Cruz 1993;88:89-95.
10. Radke MG, Berrios-Duran LA, Moran K. A perfusion procedure (Perf- O-Suction) for recovery of schistosome worms. J Parasitol 1961;47:366-8.
11. Pellegrino J, Katz N. Experimental chemotherapy of schistosomiasis mansoni. Adv Parasitol 1968;6:233-90.
12. Kemp HA, Hunter GW III, Wilkins OP, Smalley H, Dashiell MA. Studies on schistosomiasis. XI. Some ointments examined for protection against Schistosoma mansoni cercariae in preliminary tests. Mil Med 1956;119:1-10.
13. Tsang VCW, Peralta JM, Simons AR. Enzyme-linked immunoelectro- transfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. Methods Enzy- mol 1983;92:377-91.
14. Tsang VCW, Wilkins PP. Immunodiagnosis of schistosomiasis: screen with FAST-ELISA and confirm with immunoblot. Clin Lab Med 1991;11:1029-39.
15. Tsang VCW, Boyer AE, Pilcher JB, et al. Guatemalan human onchocerciasis. I. Systematic analysis of patient populations, nodular antigens, and specific isotypic reactions. J Immunol 1991; 146:3993-4000.
16. Boyer AE, Tsang VCW, Eberhard ML, et al. Guatemalan human onchocerciasis. II. Evidence for IgG3 involvement in acquired immunity to Onchocerca volvulus and identification of possible immune-associated antigens. J Immunol 1991; 146:4001-10.
17. Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmacol Ther 1985;29:129-56.
18. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DHG. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes: an example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 1978;14:281-91.
19. Craft JC, Holt EA, Tan SH. Malabsorption of oral antibiotics in humans and rats with giardiasis. Pediatr Infect Dis J 1987;6:832-6.
20. Wilkins HA, Goll P, Marshall TFC, Moore P. The significance of proteinuria and haematuria in Schistosoma haematobium infection. Trans R Soc Trop Med Hyg 1979;73:74-80.
21. Stephenson LS, Latham MC, Kinoti SN, Oduori ML. Sensitivity and specificity of reagent strips in screening of Kenyan children for Schistosoma haematobium infection. Am J Trop Med Hyg 1984;33:862-71.
22. Doehring E, Reider F, Schmidt-Ehry G, Ehrich JHH. Reduction of pathological findings in urine and bladder lesions in infection with Schistosoma haematobium after treatment with praziquantel. J Infect Dis 1985;152:807-10.
23. Schutte CHJ, Osman Y, Van Deventer JMG, Mosese G. Effectiveness of praziquantel against the South African strains of Schistosoma haematobium and S. mansoni. S Afr Med J 1983;64:7-10.
24. King CH, Wiper DW III, de Stigter KV, et al. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg 1989;40:507-13.
25. Mott KE, Dixon H, Osei-Tutu E, England EC, Davis A. Effect of praziquantel on hematuria and proteinuria in urinary schistosomiasis. Am J Trop Med Hyg 1985;34:1119-26.
26. Sarda RK, Kihamia CM, Minjas JN, Mahikwano LF. Haematuria and proteinuria in urinary schistosomiasis: response to therapy with praziquantel in Tanzanian children. Trop Med Parasitol 1987;38:31-3.
27. Wilkins HA, Moore PJ. Comparative trials of regimes for the treatment of urinary schistosomiasis in The Gambia. J Trop Med Hyg 1987;90:83-92.
28. Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzneimittelforschung 1984; 34:1132-6.
29. Anderson RM. Determinants of infection in human schistosomiasis. Bailliere’s clinical tropical medicine and communicable diseases 1987;2:279-300.
30. Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exper Parasitol 1990;71:245-8.
31. Wilkins PP, Maddison SE, Slemenda SB, Tsang VCW. Isotypic analysis of humoral immune responses in rhesus monkeys to an adult microsomal antigen of Schistosoma mansoni: an indicator of successful treatment. Am J Trap Med Hyg 1991;45:629-35.
32. Warren KS, Mahmoud AAF, Muruka JF, Whittaker LR, Ouma JH, Siongok TKA. Schistosomiasis haematobia in Coast Province Kenya: relationship between egg output and morbidity. Am J Trop Med Hyg 1979;28:864-70.
33. King CH, Keating CE, Muruka JF, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988;39:361-8.
34. King CH, Lombardi G, Lombardi C, et al. Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. Am J Trop Med Hyg 1988;39:295-305.
35. Forsyth DM, MacDonald G. Urological complications of endemic schistosomiasis in school-children. Part 1. Usagara School. Trans R Soc Trop Med Hyg 1965;59:171-8.
36. Forsyth DM, MacDonald G. Urological complications of endemic schistosomiasis in schoolchildren. Part 2. Donge School, Zanzibar. Trans R Soc Trop Med Hyg 1966;60:568-78.
37. Centers for Disease Control and Prevention. Schistosomiasis in U.S. Peace Corps volunteers—Malawi, 1992. MMWR Morb Mortal Wkly Rep 1993;42:565-70.
38. Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993;7:635-53.
39. Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs 1991;42:379-405.
40. Braun-Munzinger RA, Southgate BA. Egg viability in urinary schistosomiasis. I. New methods compared with available methods. J Trop Med Hyg 1993;96:22-7.
41. Mc Mahon JE, Kolstrup N. Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J 1979;2:1396-9.